Inter-individual variability in equine antibody responses to African snake venoms follows heavy-tailed distributions with implications for antivenom production

Posted by
  Inter-individual variability in equine antibody responses to African snake venoms follows heavy-tailed distributions with implications for antivenom production Abstract Variability in the antibody response of horses used for snake antivenom manufacture is well recognized, yet its statistical structure and implications for industrial productivity remain poorly characterized. In this study, we quantified antivenom antibody titers by ELISA in a cohort of 14 horses immunized with venoms from the clinically most important snakes in sub-Saharan Africa. To integrate antibody levels with plasma availability, we calculated the Cumulative Plasma Productivity (CPP) by converting individual plasma volumes into titer-corrected equivalents and sequentially pooling these volumes according to their corrected contribution. Distributional analysis revealed right-skewed, heavy-tailed patterns better approximated by a log-normal model than by a strict Pareto (power-law) form, with approximately 20–3...

A Paradigm Shift in Snakebite Envenoming Therapy: From Conventional Antivenoms to Rationally Designed, Broadly Neutralizing Combination Therapies

Posted by

 


A Paradigm Shift in Snakebite Envenoming Therapy: From Conventional Antivenoms to Rationally Designed, Broadly Neutralizing Combination Therapies

Abstract

For over a century, polyclonal antivenom has been the cornerstone of snakebite therapy, saving countless lives. However, the current production method, based on immunizing large animals, has inherent limitations in terms of safety, stability, and supply reliability, thereby creating a pressing need for alternative technologies. This review charts the rise of next-generation antivenoms built on recombinant antibody engineering. We systematically survey the strategies for discovering and developing these molecules, from humanized monoclonal antibodies and VHHs to computationally designed proteins. Our central thesis is that achieving broad-spectrum neutralization against complex venoms requires a shift from single-agent approaches to rationally designed, oligoclonal “cocktail” therapies (defined mixtures of a few select therapeutic antibodies). Finally, we analyze the critical challenges in bioprocessing, formulation, and regulatory science that must be overcome to translate these promising candidates from the laboratory into globally accessible medicines, and we explore the role of emerging technologies in accelerating this transition.

A Paradigm Shift in Snakebite Envenoming Therapy: From Conventional Antivenoms to Rationally Designed, Broadly Neutralizing Combination Therapies
Ning Shi, Jie Wang, Can Xu, Xingjun Jiang, Caiping Ren, Xiang Gao, and Longlong Luo
ACS Pharmacology & Translational Science Article ASAP
DOI: 10.1021/acsptsci.6c00130